Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
Le Lézard21m
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...
Le Lézard21m
Hearing Aid Specialist Makes Top Jobs' Lists
The International Hearing Society is pleased to share that the U.S. News & World Report (USNWR) January 14 edition once again ranked Hearing Aid Specialist as a best job for 2025, based on their ...